Summary by Futu AI
On August 8, 2024, Hutchison Pharma-B (02142.HK) announced that Cullinan Therapeutics, Inc. ('Cullinan') had decided to terminate the agreement on HBM7008 drug cooperation, and the termination will be effective on November 3, 2024. Hutchison Pharma-B will regain the global rights of HBM7008 and will continue to look for other opportunities for development and commercialization. The company reminds shareholders and potential investors that there is no guarantee of successful development and sales of HBM7008, and advises investors to act prudently when buying and selling shares.